InnoCan Pharma Corporation INNPF
Set alert
1.29 USD 0.00 0.00%
At close · Oct 30
1.29 Day range 1.29
1.25 52-week range 12.96
- YTD
- -82.16%
- 1 year
- -89.69%
- Open
- 1.29
- Prev close
- 1.29
- Mkt cap
- 5.80M
- Vol
- 100
- Avg vol
- 22
- EPS
- -0.26
- P/E
- 0.00
More statistics
- Low
- 1.29
- High
- 1.29
6M chart
Signals (11)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 6 days ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| RSI: Oversold | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| RSI: Oversold | Aug 4, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 30, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | May 21, 2026 | 5 months ago |
| MACD: Buy Signal | May 8, 2026 | 5 months ago |
| MACD: Sell Signal | May 5, 2026 | 6 months ago |
News
- VALITIC™ Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA
- Innocan Pharma Announces Private Placement of Units
- Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust
- Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
- Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
- Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
- FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
- Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
- Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
- Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Your note
Sign in to keep a note on INNPF — it syncs with the Stock Master app.